Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17619476 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL17619475 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL10130029 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL17610275 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL15218647 | 0.91 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL16472423 | 0.91 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL15883697 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL30232243 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL2621382 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL2621378 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3594202-B1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-11 | — | — | EP | disclosed |
| US-11034700-B2 | Substituted pyrrolidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| US-20200392149-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-17 | — | — | US | disclosed |
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| EP-3194377-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2686321-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9428511-B2 | Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428511-B2 | Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| WO-2012125893-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120035154-A1 | Modulators of Cellular Adhesion | SARcode Bioscience, Inc. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8071617-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| US-7989626-B2 | Modulators of cellular adhesion | SAR code Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110124669-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | SMN1; SMN2 3689/4885NPC1 1533/4885RAB9A 3350/4885 |
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | HCCS, TP53, NME2 | SMN1; SMN2 2746/4885NPC1 2481/4885RAB9A 1803/4885 |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | SMN1; SMN2 3860/4885NPC1 3081/4885RAB9A 2907/4885 |
| US-11034700-B2 | Substituted pyrrolidine compound and use thereof | HCRTR2, HCRTR1, CRHR2 | SMN1; SMN2 1177/4885NPC1 837/4885RAB9A 2513/4885 |
| US-20110124625-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | SMN1; SMN2 2217/4885NPC1 2049/4885RAB9A 1028/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | SMN1; SMN2 4827/4885NPC1 4824/4885RAB9A 2466/4885 |
| US-20110124669-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | SMN1; SMN2 2217/4885NPC1 2049/4885RAB9A 1028/4885 |
| US-20120035154-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | SMN1; SMN2 2217/4885NPC1 2049/4885RAB9A 1028/4885 |
| US-20200392149-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CRHR2 | SMN1; SMN2 1177/4885NPC1 837/4885RAB9A 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.